NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

CompletedPhase 4

Sponsor: Genzyme, a Sanofi Company

Conditions: Multiple Sclerosis

Interventions: Blood draw for future biomarker analysis

Countries: United States

Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing pre-identified candidate single nucleotide polymorphisms (SNPs) associated to the development of ITP after LEMTRADA treatment in RMS participants.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion criteria :

* Male and female adult participants who had been treated with LEMTRADA, with development of ITP subsequent to treatment. Participants does not need to be currently on LEMTRADA treatment.
* Participants who had signed the study ICF.

Exclusion criteria:

\- Not applicable

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Locations (1)

Los Angeles, California, United States